You can find a selection of our global flagship products on this page. However, please note that our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations; thus, in compliance with such regulations, we cannot provide detailed information about our prescription medicines on this website. Visit the applicable local Daiichi Sankyo affiliate company websites via the "Worldwide" link below to find product information in your region or country. Finally, any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.

Worldwide

Flagship Products

ENHERTU®

trastuzumab deruxtecan
(fam-trastuzumab deruxtecan-nxki in the United States only)

ENHERTU (5.4 mg/kg) is approved in more than 50 countries for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received a (or one or more) prior antiHER2-based regimen, either in the metastatic setting or in the neoadjuvant or adjuvant setting, and have developed disease recurrence during or within six months of completing therapy based on the results from the DESTINY-Breast03 trial. ENHERTU (5.4 mg/kg) is approved in more than 40 countries for the treatment of adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/in-situ hybridization (ISH)-) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy based on the results from the DESTINY-Breast04 trial.

ENHERTU (5.4 mg/kg) is approved in Israel and under accelerated approval in the U.S. for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy based on the results from the DESTINY-Lung02 trial. Continued approval in the U.S. for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

ENHERTU (6.4 mg/kg) is approved in more than 30 countries for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen based on the results from the DESTINY-Gastric01 and/or DESTINY-Gastric02 trials.

Available RegionUS, EU, UK, Japan & ASCA (Asia, South and Central America)

TURALIO®

pexidartinib

TURALIO (pexidartinib) is an oral small molecule that targets colony stimulating factor 1 receptor (CSF1R), KIT proto-oncogene receptor tyrosine kinase (KIT), and FMS-like tyrosine kinase 3 (FLT3) harboring an internal tandem duplication (ITD) mutation.

TURALIO is approved in the U.S. for the treatment of adult patients with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery. The medicine was granted Priority Review, Breakthrough Therapy and Orphan Drug Designation by the U.S. FDA prior to FDA approval in August 2019.

Available RegionUS

VANFLYTA®

quizartinib

VANFLYTA is a FLT3 inhibitor approved in Japan for the treatment of adult patients with acute myeloid leukemia (AML) that is FLT3-ITD mutation positive, including for use in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy and as maintenance monotherapy for newly diagnosed FLT3-ITD positive AML, based on the results of the QuANTUM-First trial, and as a monotherapy for relapsed/refractory AML that is FLT3-ITD positive, as detected by an approved test, based on the results of the QuANTUM-R trial.

VANFLYTA is approved in the US in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed AML that is FLT3-ITD positive, as detected by an FDA-approved test.

Available RegionUS, Japan

Injectafer®

ferric carboxymaltose injection

INJECTAFER (ferric carboxymaltose injection) is indicated for the treatment of iron deficiency in adult patients with heart failure; iron deficiency anemia (IDA) in adult and pediatric patients 1 year of age and older who have either intolerance to oral iron or an unsatisfactory response to oral iron; and adult patients with IDA who have non-dialysis dependent chronic kidney disease.

Available RegionUS

LIXIANA®/SAVAYSA®

edoxaban

Oral, once-daily, direct factor Xa (pronounced “Ten A”) inhibitor.
More than 100,000 patients worldwide are expected to participate in the edoxaban clinical research program, EDOSURE, which is comprised of more than 10 RCTs (randomized, controlled trials), non-interventional studies and registries, including completed, ongoing and future research.

Available RegionUS, EU, Japan, ASCA

MINNEBRO®

esaxerenone

Antihypertensive agent

Available RegionJapan

Select your country

OLMETEC®/OLMETEC PLUS®; REZALTAS®; SEVIKAR®/SEVIKAR HCT®

olmesartan medoxomil

Antihypertensive agent

Available RegionEU, Japan, ASCA

NILEMDO®/NUSTENDI®

bempedoic acid / fixed-dose combination of bempedoic acid and ezetimibe

NILEMDO® (bempedoic acid) is a new, first-in-class, oral, once-daily treatment which lowers cholesterol, and can be combined with other lipid-lowering therapies to help lower cholesterol even further.

NUSTENDI® is a fixed-dose combination tablet of bempedoic acid and ezetimibe which combines two complementary ways of reducing colesterol.

Available RegionEU

Select your country

EFIENT®

prasugrel

Anti-platelet agent

Available RegionJapan & ASCA

Select your country

CANALIA®

teneligliptin, canagliflozin

Treatment for Type 2 diabetes mellitus

Available RegionJapan

Select your country

Emgality®

galcanezumab-gnlm

Preventive treatment for migraine attacks

Available RegionJapan

Select your country

PRALIA®

denosumab (genetic recombination)

Treatment for osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis

Available RegionJapan

Select your country

RANMARK®

denosumab (genetic recombination)

Treatment for bone complications caused by bone metastases from tumors

Available RegionJapan

Select your country

TARLIGE®

mirogabalin

Treatment for neuropathic pain

Available RegionJapan & ASCA

Select your country

TENELIA®

teneligliptin hydrobromide hydrate

Treatment for Type 2 diabetes mellitus

Available RegionJapan

Select your country

Venofer®

iron sucrose

Treatment for iron deficiency anemia

Available RegionUS

Select your country

VIMPAT®

lacosamide

Anti-seizure medication

Available RegionJapan

REYVOW®

lasmiditan

Acute treatment for migraine attacks

Available RegionJapan

Select your country

Influenza HA Vaccine

Influenza HA vaccine

Vaccine for influenza infection

Available RegionJapan

Select your country

FLUMIST® INTRANASAL SPRAY

Intranasal Live Attenuated Influenza Vaccine

Vaccine for influenza infection

Available RegionJapan

Select your country

Adsorbed Cell Culture-derived Influenza Vaccine (H5N1)

Adsorbed cell culture-derived influenza vaccine (H5N1)

Vaccine for influenza infection

Available RegionJapan

Select your country

Measles Rubella Combined Vaccine

Measles Rubella combined vaccine

Vaccine for Measles/Rubella infection

Available RegionJapan

Select your country

Mumps Vaccine

Mumps vaccine

Vaccine for Mumps infection

Available RegionJapan

Select your country

ENHERTU®

trastuzumab deruxtecan
(fam-trastuzumab deruxtecan-nxki in the United States only)

ENHERTU (5.4 mg/kg) is approved in more than 50 countries for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received a (or one or more) prior antiHER2-based regimen, either in the metastatic setting or in the neoadjuvant or adjuvant setting, and have developed disease recurrence during or within six months of completing therapy based on the results from the DESTINY-Breast03 trial. ENHERTU (5.4 mg/kg) is approved in more than 40 countries for the treatment of adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/in-situ hybridization (ISH)-) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy based on the results from the DESTINY-Breast04 trial.

ENHERTU (5.4 mg/kg) is approved in Israel and under accelerated approval in the U.S. for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy based on the results from the DESTINY-Lung02 trial. Continued approval in the U.S. for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

ENHERTU (6.4 mg/kg) is approved in more than 30 countries for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen based on the results from the DESTINY-Gastric01 and/or DESTINY-Gastric02 trials.

Available RegionUS, EU, UK, Japan & ASCA (Asia, South and Central America)

TURALIO®

pexidartinib

TURALIO (pexidartinib) is an oral small molecule that targets colony stimulating factor 1 receptor (CSF1R), KIT proto-oncogene receptor tyrosine kinase (KIT), and FMS-like tyrosine kinase 3 (FLT3) harboring an internal tandem duplication (ITD) mutation.

TURALIO is approved in the U.S. for the treatment of adult patients with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery. The medicine was granted Priority Review, Breakthrough Therapy and Orphan Drug Designation by the U.S. FDA prior to FDA approval in August 2019.

Available RegionUS

VANFLYTA®

quizartinib

VANFLYTA is a FLT3 inhibitor approved in Japan for the treatment of adult patients with acute myeloid leukemia (AML) that is FLT3-ITD mutation positive, including for use in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy and as maintenance monotherapy for newly diagnosed FLT3-ITD positive AML, based on the results of the QuANTUM-First trial, and as a monotherapy for relapsed/refractory AML that is FLT3-ITD positive, as detected by an approved test, based on the results of the QuANTUM-R trial.

VANFLYTA is approved in the US in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed AML that is FLT3-ITD positive, as detected by an FDA-approved test.

Available RegionUS, Japan

Injectafer®

ferric carboxymaltose injection

INJECTAFER (ferric carboxymaltose injection) is indicated for the treatment of iron deficiency in adult patients with heart failure; iron deficiency anemia (IDA) in adult and pediatric patients 1 year of age and older who have either intolerance to oral iron or an unsatisfactory response to oral iron; and adult patients with IDA who have non-dialysis dependent chronic kidney disease.

Available RegionUS

LIXIANA®/SAVAYSA®

edoxaban

Oral, once-daily, direct factor Xa (pronounced “Ten A”) inhibitor.
More than 100,000 patients worldwide are expected to participate in the edoxaban clinical research program, EDOSURE, which is comprised of more than 10 RCTs (randomized, controlled trials), non-interventional studies and registries, including completed, ongoing and future research.

Available RegionUS, EU, Japan, ASCA

MINNEBRO®

esaxerenone

Antihypertensive agent

Available RegionJapan

Select your country

OLMETEC®/OLMETEC PLUS®; REZALTAS®; SEVIKAR®/SEVIKAR HCT®

olmesartan medoxomil

Antihypertensive agent

Available RegionEU, Japan, ASCA

NILEMDO®/NUSTENDI®

bempedoic acid / fixed-dose combination of bempedoic acid and ezetimibe

NILEMDO® (bempedoic acid) is a new, first-in-class, oral, once-daily treatment which lowers cholesterol, and can be combined with other lipid-lowering therapies to help lower cholesterol even further.

NUSTENDI® is a fixed-dose combination tablet of bempedoic acid and ezetimibe which combines two complementary ways of reducing colesterol.

Available RegionEU

Select your country

EFIENT®

prasugrel

Anti-platelet agent

Available RegionJapan & ASCA

Select your country

CANALIA®

teneligliptin, canagliflozin

Treatment for Type 2 diabetes mellitus

Available RegionJapan

Select your country

Emgality®

galcanezumab-gnlm

Preventive treatment for migraine attacks

Available RegionJapan

Select your country

PRALIA®

denosumab (genetic recombination)

Treatment for osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis

Available RegionJapan

Select your country

RANMARK®

denosumab (genetic recombination)

Treatment for bone complications caused by bone metastases from tumors

Available RegionJapan

Select your country

TARLIGE®

mirogabalin

Treatment for neuropathic pain

Available RegionJapan & ASCA

Select your country

TENELIA®

teneligliptin hydrobromide hydrate

Treatment for Type 2 diabetes mellitus

Available RegionJapan

Select your country

Venofer®

iron sucrose

Treatment for iron deficiency anemia

Available RegionUS

Select your country

VIMPAT®

lacosamide

Anti-seizure medication

Available RegionJapan

REYVOW®

lasmiditan

Acute treatment for migraine attacks

Available RegionJapan

Select your country

Influenza HA Vaccine

Influenza HA vaccine

Vaccine for influenza infection

Available RegionJapan

Select your country

FLUMIST® INTRANASAL SPRAY

Intranasal Live Attenuated Influenza Vaccine

Vaccine for influenza infection

Available RegionJapan

Select your country

Adsorbed Cell Culture-derived Influenza Vaccine (H5N1)

Adsorbed cell culture-derived influenza vaccine (H5N1)

Vaccine for influenza infection

Available RegionJapan

Select your country

Measles Rubella Combined Vaccine

Measles Rubella combined vaccine

Vaccine for Measles/Rubella infection

Available RegionJapan

Select your country

Mumps Vaccine

Mumps vaccine

Vaccine for Mumps infection

Available RegionJapan

Select your country